Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Antibody Response after First-dose of ChAdOx1-nCOV (Covishield™®) and BBV-152 (Covaxin™®) amongst Health Care Workers in India: Preliminary Results of Cross-sectional Coronavirus Vaccine-induced Antibody Titre (COVAT) study

View ORCID ProfileAwadhesh Kumar Singh, Sanjeev Ratnakar Phatak, Nagendra Kumar Singh, Arvind Gupta, Arvind Sharma, Kingshuk Bhattacharjee, Ritu Singh
doi: https://doi.org/10.1101/2021.04.07.21255078
Awadhesh Kumar Singh
1Consultant Endocrinologist, G. D Hospital & Diabetes Institute, Kolkata, West Bengal, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Awadhesh Kumar Singh
  • For correspondence: draksingh_2001@yahoo.com drawadheshkumarsingh@gmail.com
Sanjeev Ratnakar Phatak
2Consultant Physician & Diabetologist, Vijayratna Diabetes Centre, Ahmedabad, Gujarat, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nagendra Kumar Singh
3Director, Diabetes and Heart Research Centre, Dhanbad, Jharkhand, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arvind Gupta
4Head, Department of Diabetes, Obesity and Metabolic Disorders, Rajasthan Hospital, Jaipur, Rajasthan, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arvind Sharma
5Associate Professor, Dept. of Community Medicine, Mahatma Gandhi Medical College & Hospital, Jaipur, Rajasthan, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kingshuk Bhattacharjee
6Independent Biostatistician, Kolkata, West Bengal, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ritu Singh
7Consultant Gynecologists, G. D Hospital & Diabetes Institute, Kolkata, West Bengal, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Two vaccines are currently being administered in India to prevent the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We assessed the humoral immune response after the first dose of two vaccines ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) in Indian health care workers (HCW).

Methods This ongoing, Pan-India, Cross-sectional, Coronavirus Vaccine-induced Antibody Titre (COVAT) study is being conducted amongst HCW, with or without past history of SARS-CoV-2 infection. SARS-CoV-2 anti-spike binding antibody is being assessed quantitatively at four timepoints between 21 days or more after the first dose to 6 months after the second dose. Primary aim is to analyze antibody response following each dose of both vaccines and its correlation to age, sex, body mass index (BMI) and comorbidities. Here we report the preliminary results of anti-spike antibody response after the first dose.

Results Amongst the 552 HCW (325 Male, 227 Female), 456 and 96 received first dose of Covishield and Covaxin respectively. Overall, 79.3% showed seropositivity after the first dose. Responder rate and median (IQR) rise in anti-spike antibody was significantly higher in Covishield vs. Covaxin recipient (86.8 vs. 43.8%; 61.5 vs. 6 AU/ml; both p<0.001). This difference persisted in propensity-matched (age, sex and BMI) analysis in 172 subjects. No difference was observed with age, gender and BMI. History of hypertension had lower responder rate (65.7 vs. 82.3%, p=0.001). Covishield recipient had more adverse event vs. Covaxin arm (46.7 vs. 31.2%, p=0.006). Presence of comorbidities, past SARS-CoV-2 infection and vaccine types used were independent predictors for seropositivity after the first dose, in multiple logistic regression analysis.

Conclusions While both vaccines elicited immune response, seropositivity rates to anti-spike antibody were significantly higher in Covishield recipient compared to Covaxin after the first dose. Ongoing COVAT study will further enlighten the immune response between two vaccines after the second dose.

Highlights

  1. This study evaluated the humoral antibody response of two SARS-CoV-2 vaccines Covishield™ and Covaxin™ in Indian health-care workers.

  2. Both vaccines showed seropositivity to anti-spike antibody, 21 days or more after the first dose.

  3. Responder rates were higher in Covishield recipient compared to Covaxin in propensity-matched cohorts.

  4. Past SARS-CoV-2 infection, presence of comorbidities and vaccine type received were independent predictors of antibody response after the first dose.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

No external funding was received.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This cross-sectional study that was approved by the ethical committee of Thakershy Charitable Trust, Ahmedabad, Gujrat, India.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All the authors are responsible for the originality of this study. Original data can be shared from first author if necessary, after a reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted April 13, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Antibody Response after First-dose of ChAdOx1-nCOV (Covishield™®) and BBV-152 (Covaxin™®) amongst Health Care Workers in India: Preliminary Results of Cross-sectional Coronavirus Vaccine-induced Antibody Titre (COVAT) study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Antibody Response after First-dose of ChAdOx1-nCOV (Covishield™®) and BBV-152 (Covaxin™®) amongst Health Care Workers in India: Preliminary Results of Cross-sectional Coronavirus Vaccine-induced Antibody Titre (COVAT) study
Awadhesh Kumar Singh, Sanjeev Ratnakar Phatak, Nagendra Kumar Singh, Arvind Gupta, Arvind Sharma, Kingshuk Bhattacharjee, Ritu Singh
medRxiv 2021.04.07.21255078; doi: https://doi.org/10.1101/2021.04.07.21255078
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Antibody Response after First-dose of ChAdOx1-nCOV (Covishield™®) and BBV-152 (Covaxin™®) amongst Health Care Workers in India: Preliminary Results of Cross-sectional Coronavirus Vaccine-induced Antibody Titre (COVAT) study
Awadhesh Kumar Singh, Sanjeev Ratnakar Phatak, Nagendra Kumar Singh, Arvind Gupta, Arvind Sharma, Kingshuk Bhattacharjee, Ritu Singh
medRxiv 2021.04.07.21255078; doi: https://doi.org/10.1101/2021.04.07.21255078

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (175)
  • Allergy and Immunology (421)
  • Anesthesia (97)
  • Cardiovascular Medicine (901)
  • Dentistry and Oral Medicine (171)
  • Dermatology (102)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (407)
  • Epidemiology (8796)
  • Forensic Medicine (4)
  • Gastroenterology (405)
  • Genetic and Genomic Medicine (1864)
  • Geriatric Medicine (179)
  • Health Economics (388)
  • Health Informatics (1292)
  • Health Policy (644)
  • Health Systems and Quality Improvement (493)
  • Hematology (207)
  • HIV/AIDS (396)
  • Infectious Diseases (except HIV/AIDS) (10577)
  • Intensive Care and Critical Care Medicine (564)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (218)
  • Neurology (1762)
  • Nursing (104)
  • Nutrition (267)
  • Obstetrics and Gynecology (343)
  • Occupational and Environmental Health (461)
  • Oncology (966)
  • Ophthalmology (283)
  • Orthopedics (107)
  • Otolaryngology (177)
  • Pain Medicine (118)
  • Palliative Medicine (43)
  • Pathology (265)
  • Pediatrics (557)
  • Pharmacology and Therapeutics (266)
  • Primary Care Research (221)
  • Psychiatry and Clinical Psychology (1846)
  • Public and Global Health (3992)
  • Radiology and Imaging (655)
  • Rehabilitation Medicine and Physical Therapy (344)
  • Respiratory Medicine (536)
  • Rheumatology (216)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (166)
  • Surgery (197)
  • Toxicology (37)
  • Transplantation (107)
  • Urology (80)